Every Form 4 that TEVA PHARM INDUS LTD (TEVJF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TEVJF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TEVJF filings page.
TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD) reported insider transactions by Chief Accounting Officer Amir Weiss on 2026-08-21. Weiss exercised stock options covering 2,500 Ordinary Shares at an exercise price of $19.16 per share and then sold a total of 9,445 Ordinary Shares in open-market transactions, including 6,945 shares at a weighted average price of $37.61 (in a range of $31.62 to $37.61) and 2,500 shares at $37.63 per share. The options, which expire on March 2, 2028, were originally granted in 2018 and vested in tranches from 2019 to 2022. The Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) director Ronit Satchi-Fainaro reported selling 415 Ordinary Shares on August 21, 2026 at a price of $37.25 per share in an open-market or private transaction. Following this sale, the director directly holds 111,986 Ordinary Shares, which may be represented by American Depositary Shares, each currently representing one Ordinary Share.
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) reported that executive Evan Lippman, EVP, Business Development, sold 18,600 Ordinary Shares on August 17, 2026. The shares, which may be represented by American Depositary Shares on a one-for-one basis, were sold at a weighted average price of $36.5748, with individual trades between $36.57 and $36.61. After this sale, Lippman directly holds 25,591 Ordinary Shares. The transaction was effected under a Rule 10b5-1 trading plan adopted on May 16, 2026, indicating it followed a pre-established trading schedule.
Tal Zvi Zaks, a director of TEVA PHARMACEUTICAL INDUSTRIES LTD, reported a sale of 17 Ordinary Shares on 2026-08-05 in a sale in open market or private transaction at $34.8655 per share. Following this transaction, the director directly holds 73,247 Ordinary Shares, which may be represented by American Depositary Shares. The Rule 10b5-1 trading-plan checkbox was not selected.
Teva Pharmaceutical Industries executive Placid Jover, Executive Vice President and Chief Human Resources Officer, converted 12,827 restricted share units into the same number of ordinary shares on August 3, 2026, then sold all 12,827 shares, including shares to cover tax-withholding obligations, at a weighted average $34.8757 under a Rule 10b5-1 trading plan, leaving 25,657 restricted share units outstanding from his August 2024 grant.
Teva Pharmaceutical Industries executive Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer, exercised 52,744 restricted share units into ordinary shares on August 3, 2026. He then sold 25,578 ordinary shares at a weighted average of $34.8757 per share under a Rule 10b5-1 trading plan to cover tax withholding obligations related to the RSU vesting.
Teva Pharmaceutical Industries executive Matthew Shields, EVP of Global Operations, reported an open-market sale of 9,989 Ordinary Shares. The shares were sold at an average price of $32.1901 per share, and his directly held Ordinary Share position is reported as 0 shares following the transaction. The filing notes that the Ordinary Shares may be represented by American Depositary Shares, each currently representing one Ordinary Share.
Teva Pharmaceutical Industries EVP and CFO Eliyahu Sharon Kalif sold 106,563 Ordinary Shares in an open-market transaction on June 11, 2026 at a weighted average price of $34.0954 per share. After the sale, he directly holds 65,621 Ordinary Shares.
The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025, indicating it was scheduled in advance. The filing notes that the price reflects a weighted average from multiple trades between $33.985 and $34.25 per share. Each Ordinary Share may also be represented by one American Depositary Share.
Teva Pharmaceutical Industries director Sol J. Barer exercised 21,739 restricted share units into ordinary shares. The RSUs were granted on June 5, 2025 and vested on June 5, 2026, resulting in delivery of 21,739 ordinary shares at a stated price of $0.00 per share.
Following this vesting and conversion, Barer directly holds 448,011 ordinary shares. The transaction reflects a compensation-related derivative exercise with no reported open-market buying or selling. The ordinary shares may also be represented by American Depositary Shares, each currently equal to one ordinary share.
Teva Pharmaceutical Industries director Chen Lichtenstein exercised 14,492 restricted share units into ordinary shares, increasing his direct stake to 19,296 shares. The units were granted on June 5, 2025 and vested on June 5, 2026, and each unit settled into one ordinary share at no cash cost to him.
The ordinary shares may be held directly or represented by American Depositary Shares, each currently equal to one ordinary share. The filing reflects a compensation-related equity vesting and exercise, not an open-market purchase or sale.
TEVA Pharmaceutical Industries director Rosemary A. Crane exercised 14,492 restricted share units into ordinary shares. The Form 4 shows she acquired 14,492 ordinary shares on June 5, 2026 through the conversion of vested restricted share units at a stated price of $0.00 per share.
Following this transaction, Crane directly holds 127,739 ordinary shares. The derivative position associated with these 14,492 restricted share units is now fully settled, with no remaining units from this grant. The footnotes state that each restricted share unit represented a contingent right to receive one ordinary share or its cash value and that the units were granted on June 5, 2025 and vested on June 5, 2026.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Amir Elstein exercised restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at a stated price of $0.00 per share.
After this non-cash equity compensation event, Elstein directly held 2,118,455 ordinary shares. Each restricted share unit provided a contingent right to receive one ordinary share or, at the company committee’s option, the cash value of one ordinary share. No open-market buy or sell transaction was reported in this filing.
Teva Pharmaceutical Industries director Gerald M. Lieberman exercised restricted share units into ordinary shares. On June 5, 2026, he acquired 14,492 ordinary shares at a stated price of $0.00 per share through the vesting and conversion of restricted share units granted on June 5, 2025.
Following this transaction, he directly holds 130,149 ordinary shares. The footnotes note that each restricted share unit entitled him, at settlement, to receive one ordinary share or the cash value of one ordinary share, and that ordinary shares may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries director Nisen Perry exercised previously granted restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were settled into 14,492 ordinary shares, bringing Perry’s direct holdings to 119,807 ordinary shares.
Teva Pharmaceutical Industries director Ronit Satchi-Fainaro exercised restricted share units into ordinary shares. On June 5, 2026, 14,492 restricted share units converted into 14,492 ordinary shares at a stated exercise price of $0.00 per unit, reflecting RSU vesting rather than an open-market purchase.
These RSUs were originally granted on June 5, 2025 and vested on June 5, 2026. After the settlement, Satchi-Fainaro directly holds 112,401 ordinary shares. The filing shows an acquisition of shares through equity compensation, with no reported open-market buying or selling.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Tal Zvi Zaks exercised equity awards to receive additional ordinary shares. On June 5, 2026, 14,492 restricted share units vested and were converted into 14,492 ordinary shares at no cash exercise price, increasing his directly held stake to 73,264 ordinary shares. Each restricted share unit entitled him to one ordinary share, or at the committee’s option, the cash value of one share. The restricted share units were originally granted on June 5, 2025 and fully vested one year later. The ordinary shares may also be held as American Depositary Shares, with each ADS representing one ordinary share.
Teva Pharmaceutical Industries director Roberto Mignone reported exercising restricted share units into 14,492 Ordinary Shares on June 5, 2026, at a stated price of $0.00 per share. Following this, he directly holds 119,807 Ordinary Shares.
A separate 367,600 Ordinary Shares are held of record by Swiftcurrent Master Fund Ltd., advised by Bridger Management, LLC, which Mignone manages. He may be deemed to beneficially own those shares but disclaims beneficial ownership except for his indirect pecuniary interest.
Teva Pharmaceutical Industries President and CEO Richard D. Francis reported routine equity compensation activity involving restricted share units and related share sales. He exercised 13,043 restricted share units into ordinary shares and sold 6,153 ordinary shares at $34.35 per share to cover tax withholding obligations tied to the vesting. Following these transactions, he directly holds 1,177,529 ordinary shares and 39,130 restricted share units, with the sale executed under a pre-arranged Rule 10b5-1 trading plan.
Teva Pharmaceutical Industries executive Matthew Shields exercised 16,195 restricted share units into ordinary shares and on the same day sold all 16,195 shares at an average price of $32.87. The sale, which also covered tax withholding obligations from vesting, was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2025. Following these transactions, Shields directly holds 9,989 ordinary shares.
Zaks Tal Zvi reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Tal Zvi Zaks received a grant of 7,242 restricted share units. The grant was made on May 28, 2026 as equity compensation, not as an open-market purchase.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The units vest on May 28, 2027. Following this grant, Zaks holds 7,242 restricted share units directly, each linked to an equal number of underlying ordinary shares, which may be represented by American Depositary Shares on a one-for-one basis.
Satchi-Fainaro Ronit reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director RSU grant: Director Ronit Satchi-Fainaro received 7,242 restricted share units as a compensation award. Each unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one share. The award was granted on May 28, 2026 and will vest on May 28, 2027, subject to the plan’s conditions. Following this grant, the director holds 7,242 RSUs directly, and these may be settled in ordinary shares, which can be represented by American Depositary Shares on a 1:1 basis.
Nisen Perry reported acquisition or exercise transactions in this Form 4 filing.
Teva Pharmaceutical Industries director Nisen Perry received a grant of 7,242 restricted share units. The award was granted on May 28, 2026 and will fully vest on May 28, 2027. Each restricted share unit gives a contingent right to one ordinary share or, at the committee’s option, the cash value of one ordinary share, which may be represented by American Depositary Shares.
LIEBERMAN GERALD M reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Gerald M. Lieberman reported a compensation grant of restricted share units. On May 28, 2026, he received 7,242 restricted share units, each linked to one ordinary share. These units vest on May 28, 2027, and he now holds 7,242 units directly.
Each unit represents a contingent right to receive either one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. The ordinary shares may be represented by American Depositary Shares, with each ADS currently equal to one ordinary share.
Elstein Amir reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Amir Elstein received a grant of 7,242 restricted share units. These units were awarded on May 28, 2026 and will vest on May 28, 2027. Each unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
After this grant, Elstein holds 7,242 restricted share units directly. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share.
Crane Rosemary A reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Rosemary A. Crane received a grant of 7,242 restricted share units as equity compensation. These restricted share units were awarded on May 28, 2026 and will vest on May 28, 2027, meaning she must remain eligible through that date to receive the shares.
Each restricted share unit represents a contingent right to receive one ordinary share of Teva, or at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. The ordinary shares may be represented by American Depositary Shares, with each ADS currently equal to one ordinary share. Following this award, Crane directly holds 7,242 restricted share units related to Teva ordinary shares.
Lichtenstein Chen reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Lichtenstein Chen received a grant of 7,242 Restricted Share Units (RSUs). These RSUs were granted on May 28, 2026 and are scheduled to vest on May 28, 2027, functioning as part of equity-based compensation.
Each RSU represents a contingent right to receive, at settlement, either one ordinary share or the cash value of one ordinary share, at the option of the Human Resources and Compensation Committee. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share.
BARER SOL J reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Sol J. Barer received a grant of restricted share units. On May 28, 2026, Barer was awarded 10,863 restricted share units, each representing a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The units vest on May 28, 2027, and are reported as a direct holding. Following this grant, Barer holds 10,863 restricted share units linked to the company’s ordinary shares, which may also be represented by American Depositary Shares on a one-for-one basis.
MIGNONE ROBERTO reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD director Roberto Mignone received a grant of 7,242 restricted share units on May 28, 2026. Each restricted share unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The restricted share units vest on May 28, 2027, and are reported as directly owned. Following this award, Mignone’s reported holding of restricted share units is 7,242. The ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD EVP, Business Development Evan Lippman reported an exercise-and-sell transaction in company stock. On May 14, 2026, he exercised restricted share units to acquire 85,849 Ordinary Shares at a conversion price of $0.00 per share.
On the same date, he sold a total of 41,658 Ordinary Shares at a weighted average price of $35.5842 per share, with individual sale prices ranging from $35.38 to $35.685. A footnote states that a portion of the sold shares was required to cover tax withholding obligations related to the RSU vesting, and that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan.
TEVA PHARMACEUTICAL INDUSTRIES LTD Executive Vice President and Chief Financial Officer Eliyahu Sharon Kalif reported an open-market sale of 153,251 Ordinary Shares on May 14, 2026 at a weighted average price of $35.6107 per share. The shares were sold in multiple trades between $35.59 and $35.80. After the sale, he directly holds 172,184 Ordinary Shares, indicating he retains a substantial equity stake. The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan, meaning the trade was scheduled in advance rather than timed discretionarily.
TEVA PHARMACEUTICAL INDUSTRIES LTD Chief Accounting Officer Amir Weiss reported an open-market sale of 10,679 Ordinary Shares on May 6, 2026 at $36.00 per share. After this transaction, he directly holds 20,016 Ordinary Shares, which may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries EVP Europe Commercial Richard Daniell reported an open-market sale of Teva ordinary shares. On May 5, 2026, he sold 30,000 ordinary shares at $35.40 per share. After this transaction, he directly held 55,755 ordinary shares.
The filing notes that Teva’s ordinary shares may be represented by American Depositary Shares, with each ADS currently corresponding to one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD officer Mark Sabag completed an open-market sale of 144,180 Ordinary Shares on May 1, 2026, at a weighted average price of $34.9918 per share. Following this sale, he directly holds 80,760 Ordinary Shares, which may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries EVP Christine Fox, who leads U.S. Commercial operations, reported an open-market sale of 21,258 Ordinary Shares of Teva on April 30, 2026 at a weighted average price of $35.31 per share. The filing notes these shares were sold in multiple trades between $35.28 and $35.33 per share. Following this transaction, Fox directly holds 63,647 Ordinary Shares, which may also be represented by American Depositary Shares, each currently representing one Ordinary Share.
Teva Pharmaceutical Industries officer Mark Sabag reported an open-market sale of 62,102 Ordinary Shares on March 17, 2026. The shares were sold at a weighted average price of $30.141 per share, in multiple trades between $30.115 and $30.215.
Following this transaction, Sabag directly owns 224,940 Ordinary Shares. The filing notes that each Ordinary Share may be represented by an American Depositary Share, with each ADS currently corresponding to one Ordinary Share.
Teva Pharmaceutical Industries officer Mark Sabag reported the vesting and settlement of 15,723 restricted share units on March 5, 2026. These units were converted at $0.00 per share into 15,723 ordinary shares, increasing his direct holdings to 287,042 ordinary shares.
Following the transaction, he also held 47,170 restricted share units. The RSUs were originally granted on March 5, 2025, with additional tranches of 15,723 vesting on March 5, 2027 and March 5, 2028, and 15,724 vesting on March 5, 2029. Each RSU represents a right to one ordinary share or its cash value.
Teva Pharmaceutical Industries Chief Accounting Officer Amir Weiss reported equity compensation activity involving restricted share units. On March 5, 2026, 3,537 restricted share units were converted into 3,537 ordinary shares at no cash exercise price as part of a previously granted award.
The footnotes explain this grant was made on March 5, 2025, with 3,537 units vesting on March 5, 2026, 3,537 vesting on each of March 5, 2027 and March 5, 2028, and 3,539 vesting on March 5, 2029. After this transaction, Weiss directly held 30,695 ordinary shares and 10,613 restricted share units.
Teva Pharmaceutical Industries President and CEO Richard Francis reported vesting and related transactions in company equity on March 5, 2026. He exercised 42,452 Restricted Share Units (RSUs), which converted into the same number of ordinary shares at a stated price of $0.00 per share.
Following the RSU conversion, he held 1,190,664 ordinary shares before selling 20,025 ordinary shares in open-market transactions at a weighted average price of $31.6684 per share to cover tax withholding obligations. After these sales, he directly owns 1,170,639 ordinary shares and 127,359 RSUs, each RSU representing a contingent right to one ordinary share or its cash value. The sale was made under a pre-arranged Rule 10b5-1 trading plan. Ordinary shares may be represented by American Depositary Shares on a one-for-one basis.
Teva Pharmaceutical Industries Ltd EVP, U.S. Commercial Christine Fox reported RSU vesting and related share transactions. On March 5, 2026, 17,819 restricted share units were exercised into the same number of ordinary shares at a stated price of $0.00 per share.
On the same date, she sold 7,924 ordinary shares at a weighted average price of $31.6684 per share to cover tax withholding obligations, under a Rule 10b5-1 trading plan adopted on August 11, 2025. Following these transactions, she directly held 84,905 ordinary shares.
Teva Pharmaceutical Industries executive Eric A. Hughes reported equity awards activity and a related share sale. On March 5, 2026, 19,654 restricted share units vested and were converted into 19,654 ordinary shares at no cost, increasing his direct holdings to 117,244 ordinary shares.
On the same date, he sold 9,533 ordinary shares at a weighted average price of $31.6684 per share, reducing his direct holdings to 107,711 ordinary shares. According to the disclosure, these shares were sold under a pre-established Rule 10b5-1 trading plan and were required to cover tax withholding obligations from the RSU vesting.
Footnotes add that each restricted share unit represents a right to receive one ordinary share or its cash value, and that the RSU grant from March 5, 2025 vests in four equal annual installments through March 5, 2029.
Teva Pharmaceutical Industries EVP, Europe Commercial Daniell Richard reported equity award activity and a share sale. On March 5, 2026, he exercised 17,295 restricted share units for 17,295 ordinary shares at no cost, as part of a previously granted award. The same day, he sold 17,295 ordinary shares in open-market transactions at a weighted average price of $31.6684, under a Rule 10b5-1 trading plan adopted on November 10, 2025, and in connection with the vesting of the units, including shares sold to cover tax withholding obligations. Following these transactions, he directly holds 85,755 ordinary shares and 51,887 restricted share units.
TEVA PHARMACEUTICAL INDUSTRIES LTD officer Jover Placid reported restricted share units vesting and related share sales. On March 5, 2026, 14,150 restricted share units were exercised into 14,150 ordinary shares at $0.0000 per share.
The same day, he sold 14,150 ordinary shares at a weighted average price of $31.6684 per share in open-market transactions under a Rule 10b5-1 trading plan adopted on November 10, 2025. The sale included shares to cover tax withholding on vesting. Following these transactions, he directly holds 6,774 ordinary shares and 42,453 restricted share units.
Teva Pharmaceutical Industries interim chief legal officer Brian Savage reported equity compensation activity involving restricted share units and ordinary shares. On March 5, 2026, 3,580 restricted share units were converted into 3,580 ordinary shares at a stated price of $0.00 per share, reflecting a vesting event rather than a market purchase. On the same date, he sold 1,127 ordinary shares at a weighted average price of $31.6684 per share, with the shares sold in multiple trades between $31.26 and $32.34. According to the disclosure, these shares were required to be sold to cover tax withholding obligations arising from the vesting of the restricted share units.
Teva Pharmaceutical Industries executive Matthew Shields exercised 17,295 restricted share units into ordinary shares and, on the same day, sold 17,295 ordinary shares in an open-market transaction at a weighted average price of $31.6684. The sale was executed under a Rule 10b5-1 trading plan adopted on November 10, 2025 and included shares sold to cover tax withholding obligations tied to vesting. Following these transactions, Shields directly holds 9,989 ordinary shares and 51,887 restricted share units.
Teva Pharmaceutical Industries President and CEO Richard Francis reported multiple equity transactions on ordinary shares and restricted share units. He exercised 50,223 restricted share units, receiving the same number of ordinary shares at a price of $0.00 per share, as part of a prior equity grant.
On the same date, he received a new award of 136,736 restricted share units, each representing a right to one ordinary share or its cash value at settlement. He then sold 23,393 ordinary shares at a weighted average price of $32.4645 per share, with the shares sold at prices between $32.095 and $33.30 to cover tax withholding obligations under a pre-established Rule 10b5-1 trading plan.
Following these transactions, Francis held 1,148,212 ordinary shares directly.
Teva Pharmaceutical Industries EVP, Europe Commercial Daniell Richard reported a combination of equity awards, vesting and share sales. On March 4, 2026, he exercised restricted share units into 33,512 and 20,461 ordinary shares and received a new grant of 33,424 restricted share units.
He then sold 91,345 ordinary shares in open-market transactions at weighted average prices of $32.4645 and $32.9474, executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 10, 2025. Following these trades, he directly owned 85,755 ordinary shares. The filing notes the sales related to vesting of restricted share units, including shares sold to cover tax withholding obligations.
Jover Placid reported acquisition or exercise transactions in this Form 4 filing.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported that officer Jover Placid received a grant of 37,982 restricted share units on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share, or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.
The award vests in four annual installments, with 9,495 units vesting on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 9,497 units vesting on March 4, 2030. The ordinary shares may be represented by American Depositary Shares, each currently corresponding to one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported that EVP, Global Operations Matthew Shields acquired 33,424 restricted share units as a grant on March 4, 2026. Each restricted share unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The award vests in four equal installments of 8,356 units on March 4 of 2027, 2028, 2029, and 2030. The filing notes that the company’s ordinary shares may be represented by American Depositary Shares, and that each ADS currently represents one ordinary share.
TEVA PHARMACEUTICAL INDUSTRIES LTD officer Mark Sabag reported equity compensation activity involving restricted share units and ordinary shares. On March 4, 2026, he exercised restricted share units into 33,512 ordinary shares and 18,601 ordinary shares at a price of zero per share, increasing his direct holdings. He also received a new grant of 30,385 restricted share units, scheduled to vest in annual installments from March 4, 2027 through March 4, 2030. Each restricted share unit represents a right to one ordinary share or its cash value, and the ordinary shares may be represented by American Depositary Shares.
Lippman Evan reported acquisition or exercise transactions in this Form 4 filing.
Teva Pharmaceutical Industries executive Evan Lippman, EVP of Business Development, received a grant of 27,347 restricted share units (RSUs) on March 4, 2026. Each RSU represents a contingent right to receive either one ordinary share or, at the compensation committee’s option, the cash value of one ordinary share.
The RSUs vest in four annual installments: 6,836 on each of March 4, 2027, March 4, 2028, and March 4, 2029, and 6,839 on March 4, 2030. Following this award, Lippman’s reported derivative holdings from this grant total 27,347 RSUs. The filing notes that Teva’s ordinary shares may be represented by American Depositary Shares, each currently equal to one ordinary share.